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YEAR IN CARDIOLOGY SERIES YEAR IN CARDIOLOGY SERIESThe Year in Acute Coronary Syndrome 201
Robert P. Giugliano, Eugene Braunwald
In this year’s report on acute coronary syndromes (ACS), Giugliano and Braunwald review
selected papers broadly related to the spectrum of ACS published between June 2012 and
September 2013.STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPERAutonomic Modulation for Treating AF 215Dominik Linz, Christian Ukena, Felix Mahfoud, Hans-Ruprecht Neuberger, Michael Böhm
In this state-of-the-art paper, Linz and colleagues discuss the role of the autonomic nervous
system in the pathogenesis of atrial ﬁbrillation (AF). The potential antiarrhythmic and/or
arrhythmogenic effects of modulation of the autonomic nervous system are also reviewed.
Techniques for autonomic modulation include: renal sympathetic denervation, ganglionated
plexi ablation, ganglion stellatum ablation, high thoracic epidural anesthesia, low-level vagal
nerve stimulation, and baroreﬂex stimulation. The potential for each of these techniques to
treat or prevent AF is reviewed.(continued on page A-25)
JANUARY 28, 2014 (continued) A-25CLINICAL RESEARCH ANTIPLATELET THERAPYDischarge Aspirin Dose and Outcomes in ACS 225
Payal Kohli, Jacob A. Udell, Sabina A. Murphy, Christopher P. Cannon, Elliott M. Antman,
Eugene Braunwald, Stephen D. Wiviott
Optimal aspirin dosing following acute coronary syndrome (ACS) remains uncertain.
Kohli and colleagues reviewed data from the TRITON–TIMI 38 (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–
Thrombolysis in Myocardial Infarction 38), with 12,860 patients classiﬁed into low-dose
(<150 mg) or high-dose (150 mg) aspirin groups. There was signiﬁcant geographical
variation in aspirin dosing, with North American patients receiving high-dose aspirin more
frequently than those in other countries (66% vs. 28%). Regardless of low- or high-dose
aspirin, prasugrel had lower rates of the primary efﬁcacy endpoint and higher rates of the
primary safety endpoint compared with clopidogrel. These results suggest that there is no
clinically meaningful interaction of aspirin dose with prasugrel.ANTIPLATELET THERAPYPlatelet Activity After Stopping Clopidogrel 233
Isobel Ford, Neil W. Scott, Vera Herd, Louise R. Mitchell, David J. P. Williams, Julie Brittenden
The aim of this randomized, placebo-controlled trial was to determine if withdrawing
clopidogrel therapy leads to increased platelet activity compared with pre-treatment values.
A total of 171 patients on aspirin therapy were randomized to placebo or clopidogrel (75 mg
daily) for 28 days. Blood samples were taken at baseline, on treatment, and on days 7, 14, and
28 following discontinuation. Adenosine diphosphate-stimulated platelet ﬁbrinogen binding,
P-selectin expression, and platelet aggregation were lower on treatment with clopidogrel
compared with baseline, but returned to baseline levels by 7 days after discontinuation. This
trial found no evidence for rebound of platelet activity to above baseline levels after stopping
clopidogrel.(continued on page A-26)
JANUARY 28, 2014 (continued) A-26HEART FAILUREIncreased Need for Right Ventricular Support in Patients With CCMP 240
Guilherme H. Oliveira, Matthias Dupont, David Naftel, Susan L. Myers, Ya Yuan, W. H. Wilson Tang,
Gonzalo Gonzalez-Stawinski, James B. Young, David O. Taylor, Randall C. Starling
Oliveira and colleagues reviewed data from the INTERMACS registry (Interagency Registry
for Mechanically Assisted Circulatory Support) regarding the use of mechanical circulatory
support (MCS) in patients with chemotherapy-induced cardiomyopathy (CCMP). CCMP
patients were more often female, more often had MCS implanted as destination therapy,
required more right ventricular assist device support, and had a higher risk of bleeding
compared with other patients undergoing MCS. Survival of CCMP patients was similar to
that of patients with either ischemic or nonischemic cardiomyopathies undergoing MCS.
Editorial Comment: Peter M. Eckman, Ranjit John, p. 249HEART FAILUREAngina in Heart Failure With Preserved EF 251
Robert J. Mentz, Samuel Broderick, Linda K. Shaw, Mona Fiuzat, Christopher M. O’Connor
Mentz and colleagues investigated the impact of angina pectoris (AP) for predicting
outcomes in patients with heart failure with preserved ejection fraction (HFpEF). HFpEF
patients who underwent coronary angiography at Duke University Medical Center and had at
least 1 >50% coronary stenosis were studied. After multivariable adjustment, those with AP
remained at increased risk for major adverse cardiovascular events (MACE) and death,
myocardial infarction, or revascularization, but were at similar risk for other endpoints. AP in
HFpEF patients with a history of coronary artery disease is common despite medical therapy
and is independently associated with increased MACE due to revascularization, with similar
risk of death, myocardial infarction, and hospitalization.(continued on page A-27)
JANUARY 28, 2014 (continued) A-27HEART RHYTHM DISORDERSFamilial Idiopathic VF Linked to a CALM1 Mutation 259
Roos F. Marsman, Julien Barc, Leander Beekman, Marielle Alders, Dennis Dooijes,
Arthur van den Wijngaard, Ilham Ratbi, Abdelaziz Seﬁani, Zahurul A. Bhuiyan,
Arthur A. M. Wilde, Connie R. Bezzina
Marsman and colleagues describe their investigation to identify the genetic defect in a family
with idiopathic ventricular ﬁbrillation (VF). Two siblings died suddenly at the ages of 9 and
10 years, and another 2 siblings were resuscitated from out-of-hospital cardiac arrest with
documented VF. No electrocardiographic or echocardiographic abnormalities were detected
among family members. Exome sequencing in the 2 resuscitated siblings identiﬁed a
missense mutation affecting a highly-conserved residue in the CALM1 gene encoding
calmodulin. The mutation was inherited from the asymptomatic mother and was present in
an asymptomatic sibling who, like the mother, displayed a marginally prolonged QT interval
during exercise.
Editorial Comment: Sumeet S. Chugh, Adriana Huertas-Vazquez, p. 267HEART VALVE DISEASETAVR in Patients With Chronic Lung Disease 269
Danny Dvir, Ron Waksman, Israel M. Barbash, Susheel K. Kodali, Lars G. Svensson, E. Murat Tuzcu,
Ke Xu, Sa’ar Minha, Maria C. Alu, Wilson Y. Szeto, Vinod H. Thourani, Raj Makkar, Samir Kapadia,
Lowell F. Satler, John G. Webb, Martin B. Leon, Augusto D. Pichard
Dvir and colleagues evaluated the impact of chronic lung disease (CLD) on outcomes of
patients with severe aortic stenosis across all treatment modalities. Patients enrolled in the
PARTNER (Placement of AoRTic TraNscathetER Valve) trials, including the continued
access registry, were evaluated according to CLD clinical severity. Among all transcatheter
aortic valve replacement (TAVR)-treated patients, patients with CLD had higher mortality
at 1 year than those without CLD. Among CLD subjects, 2-year all-cause death rates were
similar between TAVR and surgical aortic valve replacement; however, in inoperable subjects,
the death rate was lower with TAVR compared with standard medical therapy alone.(continued on page A-28)
JANUARY 28, 2014 (continued) A-28BIOMARKERSProenkephalin for Risk Stratiﬁcation After Myocardial Infarction 280
Leong L. Ng, Jatinderpal K. Sandhu, Haﬁd Narayan, Paulene A. Quinn, Iain B. Squire,
Joan E. Davies, Andreas Bergmann, Alan Maisel, Donald J. L. Jones
Enkephalins, part of the endogenous opioid system, are secreted by both myocytes and
nonmyocytes and may have an autocrine/paracrine effect. Ng and colleagues investigated the
prognostic value of proenkephalin (PENK) levels in acute myocardial infarction (AMI).
Multivariable Cox regression models showed that PENK level was a predictor of major
adverse events, death and/or AMI, death and/or heart failure (HF), and recurrent AMI.
PENK levels were independent predictors of 6-month death and/or myocardial infarction
when compared with GRACE (Global Registry of Acute Coronary Events) scores. PENK
levels reﬂect cardiorenal status post-AMI and are prognostic for death, recurrent AMI,
or HF.
